Manel Juan
Overview
Explore the profile of Manel Juan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
3955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat J, Gonzalez-Calle V, Moreno D, et al.
Blood Adv
. 2024 Nov;
9(3):571-582.
PMID: 39602341
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in...
12.
Gaimari A, De Lucia A, Nicolini F, Mazzotti L, Maltoni R, Rughi G, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596267
Recent times have witnessed remarkable progress in cancer immunotherapy, drastically changing the cancer treatment landscape. Among the various immunotherapeutic approaches, adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR) T...
13.
Abba Moussa D, Vazquez M, Chable-Bessia C, Roux-Portalez V, Tamagnini E, Pedotti M, et al.
Emerg Microbes Infect
. 2024 Nov;
14(1):2432345.
PMID: 39584380
Unlocking the potential of broadly reactive coronavirus monoclonal antibodies (mAbs) and their derivatives offers a transformative therapeutic avenue against severe COVID-19, especially crucial for safeguarding high-risk populations. Novel mAb-based immunotherapies...
14.
Bachiller M, Barcelo-Genestar N, Rodriguez-Garcia A, Alserawan L, Dobano-Lopez C, Gimenez-Alejandre M, et al.
Mol Ther
. 2024 Nov;
33(1):317-335.
PMID: 39563035
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given...
15.
Zabaleta A, Puig N, Cedena M, Oliver-Caldes A, Perez J, Moreno C, et al.
Am J Hematol
. 2024 Nov;
100(1):93-102.
PMID: 39548827
The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients...
16.
Navarro S, Moukheiber C, Inoges Sancho S, Ruiz Guillen M, Lopez-Diaz de Cerio A, Sanges C, et al.
Mol Ther
. 2024 Nov;
33(3):847-865.
PMID: 39533710
Chimeric antigen receptor (CAR)-T cell products, classified as Advanced Therapy Medicinal Products (ATMPs), have shown promising outcomes in cancer immunotherapy. The quality of raw and starting materials used in manufacturing...
17.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado J, Bataller A, Ortiz-Maldonado V, Benitez-Ribas D, et al.
Cell Rep Med
. 2024 Oct;
5(11):101803.
PMID: 39471818
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell...
18.
Panisello C, Aschero R, Martinez-Moreno A, Roca Ho H, Falgas A, Gonzalez-Navarro E, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39379097
Humanized immunodeficient mice serve as critical models for investigating the functional interplay between transplanted human cells and a pre-reconstituted human immune system. These models facilitate the study of molecular and...
19.
Gallego-Valle J, Perez-Fernandez V, Rosales-Magallares J, Gil-Manso S, Castella M, Gonzalez-Navarro E, et al.
Front Immunol
. 2024 Oct;
15:1448752.
PMID: 39364400
Introduction: Immunotherapy has revolutionized cancer treatment, and Chimeric Antigen Receptor T cell therapy (CAR-T) is a groundbreaking approach. Traditional second-generation CAR-T therapies have achieved remarkable success in hematological malignancies, but...
20.
Martinez-Vila C, Gonzalez-Navarro E, Teixido C, Martin R, Aya F, Juan M, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273452
Melanoma is the most aggressive and deadly form of skin cancer, and its incidence has been steadily increasing over the past few decades, particularly in the Caucasian population. Immune checkpoint...